Business

Indian pharma has little reason to fear Trump

By Sohail Khan 24 August 2026, 8:08 am

Benchmarks
Nifty24,252.0020.16

FEATURED FUNDS★★★★★

Motilal Oswal Midcap Fund Direct-Growth

5Y Return
24.08 %

Invest Now

Enter search text:

Business News›Industry›Healthcare/Biotech›Pharmaceuticals›Indian pharma has little reason to fear Trump

Read Today's Paper

Synopsis

US tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially cause shortages. Indian firms operate on low margins, making tariff absorption difficult. Recent US manufacturing experiences offer little incentive for relocation. Targeted incentives offer a more direct approach to supply chain resilience.

Trump tariff impact on Indian pharma industry

Indian pharmaceutical firms have spent decades supplying American patients with affordable medicines. That dominance will be difficult to challenge, despite President Donald Trump’s threat to impose steep tariffs on imported generic drugs.

His pledge last month to apply a 100% levy on companies making off-patent medications by 2028 (rising to 200% a year later) unless they move production to the US faces formidable commercial and political obstacles. Instead of rushing to fire up new manufacturing facilities, the likes of Sun Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd. would be better off biding their time. The duties may never fully materialize.

Also read: Udan vs Udaan: Delhi court restrains pharmaceutical firm from using 'Udaan' mark

That’s because generic medicines play a crucial role in the healthcare system. Once patent protections on branded drugs expire, other manufacturers can produce equivalent versions, introducing competition that drives prices sharply lower. The difference can be enormous. According to one US Food & Drug Administration study, the price of an HIV medicine, Truvada, fell from about $50 to $3 a tablet shortly after generic versions became available.

Bloomberg

Generics account for most US prescriptions

Generic drugmakers operate on high volumes and low margins. Asia’s five-biggest players have an average EBITDA margin, a measure of operating profitability, of around 22%, considerably less than the world’s top five innovative drugmakers. That reflects the economics of a business in which off-patent medicines account for more than 90% of US prescriptions but only a fraction of spending as they are so cheap. With less profit at stake, manufacturers have little incentive to shift production to the US — and no room to absorb tariffs.

Bloomberg

India dominates the region's generic medicine producers

That means the levies, if imposed, could be borne by American patients and the wider healthcare system, and ultimately feed into already stubbornly high inflation. Spencer Perlman, a healthcare analyst at Veda Partners, a consultancy firm based in Bethesda, Maryland, estimates that the threatened tariffs could increase total prescription-drug spending by roughly 8% to 15%.

And if the extra cost can’t be passed on to patients, some drugs could become unprofitable to produce, potentially leading to shortages — an even less acceptable trade-off than higher prices. A policy that would make the cheapest medicines much more expensive or unavailable would be politically unpalatable in 2028, a presidential election year.

Bloomberg

India is top source of generic pills to the US

To be sure, some Indian firms have invested in US manufacturing as part of a push into higher-margin treatments. Sun Pharmaceutical, India’s largest drugmaker, and Aurobindo Pharma Ltd. have separately announced such investments. But these are commercial decisions intended to improve profitability, not responses to the threat of tariffs.

Washington has legitimate reasons to worry about relying so heavily on overseas suppliers for essential drugs. But levies are an unusually blunt way of addressing that vulnerability. If the goal is greater resilience, then targeted incentives for strategically important medicines, diversified supply chains and guaranteed purchasing contracts would attack the problem more directly than taxing every imported generic.

The US spent four decades building a system that rewarded whoever could supply safe medicines most cheaply, and Asian companies became extraordinarily good at it. Until Washington proves it’s genuinely willing to undo all that, Indian drugmakers have little reason to panic.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

(You can now subscribe to our WhatsApp channel)

Read More News on
Indian pharmaceutical industrygeneric drugsTrump tariffsUS drug pricesSun Pharmaceutical IndustriesDr. Reddy's Laboratoriesmedication shortagesdrug manufacturing in the UShealthcare system

(Catch all the Business News, Breaking News and Latest News Updates on The .)

…moreless

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year